1. Article title:

Screening of Glypican-3 Expression in Human Normal versus Benign and Malignant Tissues: A Comparative Study Glypican-3 expression in cancers

2. Article author or authors

Yousef Al-Saraireh, Futoon Alrawashdeh, Jehad Al-Shuneigat, Mohammed Alsbou, Nedal Alnawaiseh, Hani Al-Shagahin, and Ahmed Youssef.
3. Name of journal and date of publication

Biosciences Biotechnology Research Asia (2016/6/25)

4. Article abstract

Glypican-3 is a heparan sulfate proteoglycans (HSPGs) expressed at plasma membrane surface. Several studies demonstrated the re-expression of glypican-3 during the malignant transformation. Glypican-3 expression in hepatocellular carcinoma was suggested to be a diagnostic marker for differential diagnosis of hepatic nodules. The aim of the study is to evaluate the diagnostic value of glypican-3 as tumor marker not only in liver tumors but also in tumors of the other organs. A total of 95 surgically excised human tissues were subjected to immunohistochemical staining using a monoclonal antibody specific for glypican-3. These human tissues cover most of the common normal, benign, malignant and metastatic tumors originated from 27 anatomic sites. The immunohistochemical results revealed that glypican-3 was expressed in 21.7% of the normal tissues studied including stomach, small intestine, kidney (Normal cortex), and pancreas, while, the expression for glypican-3 was positive in 42.4% of the benign and malignant tumors. The most frequent expressing tumor was hepatocellular carcinoma. Moreover, for the first time, several tumor entities showed glypican-3 expression including malignant meningioma, Hodgkin’s lymphoma, B-non Hodgkin's lymphoma,T-non Hodgkin's lymphoma.